FDA’s Antimicrobial Drugs Advisory Committee narrowly concluded that the benefits of Merck’s (NYSE:MRK) COVID-19 pill molnupiravir outweigh the risks.
A total of 13 members of the panel voted in favor of the drug candidate, while 10 voted against it. There were no abstentions.
Get the full story form our sister site, Drug Discovery & Development.